Table 2.
Chimerism and tumor response in patients with hematologic malignancies treated with a sibling graft–UMass data
| Patient no. | Disease | Maximal donor chimerism (%) | Response (disease state at 8 weeks) | Graft-vs-host disease | Survival (d) |
|---|---|---|---|---|---|
| 1 | Lymphoma | 5 | CR | No | 1765a |
| 2 | Lymphoma | 10 | Died of disease | Yes | 28 |
| 6 | Myeloma | 100 | CR | Yes | 116 |
| 8 | Myeloma | 10 | Stable | Yes | 229 |
| 9 | CML | 67 | No response | No | 129 |
| 11 | Lymphoma | 5 | Died of disease | No | 29 |
| 12 | Lymphoma | 100 | CR | Yes | 222 |
| 20 | Lymphoma | 67 | Died of disease | No | 37 |
| 23 | CLL | 0 | PR | Yes | 179 |
| 24 | Lymphoma | 0 | Died of disease | No | 40 |
| 25 | AML | 100 | CR | Yes | 1110 |
AML =acute myeloid leukemia; CLL =chronic lymphocytic leukemia; CML =chronic myeloid leukemia; CR =complete remission.
a
Patient currently alive and disease-free.